Henry Kelly E, Ulaner Gary A, Lewis Jason S
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; Department of Radiology, Weill Cornell Medical College, New York, NY 10065, USA.
PET Clin. 2017 Jul;12(3):269-288. doi: 10.1016/j.cpet.2017.02.001.
Increased human epidermal growth factor receptor 2 (HER2) expression is a hallmark of aggressive breast cancer. Imaging modalities have the potential to diagnose HER2-positive breast cancer and detect distant metastases. The heterogeneity of HER2 expression between primary and metastatic disease sites limits the value of tumor biopsies. Molecular imaging is a noninvasive tool to assess HER2-positive primary lesions and metastases. Radiolabeled antibodies, antibody fragments, and affibody molecules devise a reliable and quantitative method for detecting HER2-positive cancer using PET. HER2-targeted PET imaging is a valuable clinical tool with respect to both the care and maintenance of patients with breast cancer.
人表皮生长因子受体2（HER2）表达增加是侵袭性乳腺癌的一个标志。成像方式有潜力诊断HER2阳性乳腺癌并检测远处转移。原发性和转移性疾病部位之间HER2表达的异质性限制了肿瘤活检的价值。分子成像是评估HER2阳性原发性病变和转移灶的一种非侵入性工具。放射性标记的抗体、抗体片段和亲和体分子设计了一种使用PET检测HER2阳性癌症的可靠且定量的方法。HER2靶向PET成像对于乳腺癌患者的护理和维持都是一种有价值的临床工具。
